VKTX
Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors
Article Summary
BUY- Viking Therapeutics Inc. (NASDAQ: VKTX) announced appointment of Dorothy Gemmell to its Board of Directors effective immediately with over 25 years of leadership experience across healthcare, digital health, and commercialization.
- The clinical-stage biopharmaceutical company focused on development of novel therapies for metabolic and endocrine disorders appointed highly experienced executive and board advisor with over two decades of leadership across GoodRx, Capsule, and Havas Life.
- Viking Therapeutics is advancing next-generation portfolio of therapies for obesity and metabolic disease guided by deep expertise in metabolic biology and rigorous science, with VK2735 potentially having potential to change standard of care for weight loss and help people achieve important cardiometabolic health benefits.
- Gemmall holds Bachelor of Science in biochemistry from McGill University with proven ability to translate innovation into commercial success, build high-performing teams, and execute growth strategies in healthcare sector.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | -7.0% | 25% | 0.0 ptsNegative (-7.0%) - Declining expectations |
| Target Price Upside ? | 162.3% | 20% | 100.0 ptsMassive Upside (162.3%) - Target: $94.29 vs Current: $35.95 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | -16.7% | 15% | 40.0 ptsMild Pullback (-16.7%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About VKTX
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
- Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
- The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.
- The company was incorporated in 2012 and is headquartered in San Diego, California.